Table 1.
Demographic and Viral Characteristics of Study Subjectsa
| Characteristic | Coinfected Subjects (n = 28) | Monoinfected Subjects (n = 10) |
|---|---|---|
| Race | ||
| African American | 27 (96) | 8 (80) |
| Other | 1 (4) | 2 (20) |
| Sex | ||
| Male | 18 (64) | 6 (60) |
| Female | 10 (36) | 4 (40) |
| Age at HIV seroconversion or 1st sample,b median (range), y | 36 (26–51) | 40 (35–51) |
| Time between ALIVE study entry and pre-HIV sample, median (range), mo | 41.9 (0.6–137.7) | … |
| Time between pre-HIV sample and HIV seroconversion, median (range), mo | 8.9 (2.9–14.1) | … |
| Time between HIV seroconversion and post-HIV sample, median (range), mo | 72.0 (16.6–141.1) | … |
| Time between 1st and 2nd samples, median (range), mo | 80.5 (22.6–153.5) | 124.3 (72.4–128.2) |
| CD4+ T-cell count at 2nd sample, median (range), cells/mm3 | 284 (7–725) | 1105 (663–1137)c |
| CD4+ T-cell countc at 2nd sample, cells/mm3 | ||
| 0–199 | 10 (36) | … |
| 200–349 | 8 (29) | … |
| ≥350 | 10 (36) | … |
| HIV RNA at 2nd sample, median (range), copies/mL | 54796 (542–759 003) | … |
| Any antiretroviral therapy | 7 (25) | … |
| HAART | 1 (4) | … |
| HCV genotyped | ||
| 1 | 25 (96) | 7 (100) |
| 2 | 1 (4) | 0 (0) |
| Injection drug usee | ||
| 1st samplef | ||
| None | 6 (22) | 4 (40) |
| <1/d | 8 (30) | 4 (40) |
| ≥1/d | 13 (48) | 2 (20) |
| 2nd sample | ||
| None | 14 (50) | 8 (80) |
| <1/d | 3 (11) | 1 (10) |
| ≥1/d | 11 (39) | 1 (10) |
Abbreviations: ALIVE, AIDS Linked to the Intravenous Experience; HAART, highly active antiretroviral therapy; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
a Unless otherwise indicated, data represent No. (%) of subjects.
b Age at HIV seroconversion for HIV/HCV coinfected subjects and age at first sample for HCV monoinfected subjects.
c The CD4+ T-cell count was not measured for all monoinfected subjects (n = 3).
d The HCV genotype was unavailable for 2 coinfected subjects (n = 26) and 3 monoinfected subjects (n = 7).
e Injection drug use in the 6 months before the clinic visit.
f Information unavailable for 1 coinfected subject (n = 27).